It was previously described how recipients of an allogeneic HSCT who develop extensive chronic graft versus host disease are able to generate immune responses against wild-type NPM1 [6, 23], while CTL lines deriving from colorectal carcinoma patients may also recognize NPM1, indicating that this protein is immunogenic [24]. This evidence concerns the gene NPM1 and colorectal carcinoma.